Ernexa <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Replaces Grant Thornton Amid Internal Control Weakness_issue
Ernexa Therapeutics Inc. has announced a change in its independent registered public accounting firm, dismissing Grant Thornton LLP effective June 30, 2025, and appointing Haskell & White LLP on July 1, 2025. This decision was approved by the Audit Committee of Ernexa's Board of Directors. The company reported no disagreements or reportable events with Grant Thornton during the two years ending December 31, 2024, and the interim period through June 30, 2025, except for a noted material weakness in Ernexa's internal control over financial reporting for the year ending December 31, 2023, due to insufficient technical accounting proficiency in complex matters. Prior to the appointment, Ernexa had not consulted Haskell & White regarding any accounting principles or audit opinions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-018009), on July 07, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。